Actively Recruiting

Age: 2Years - 65Years
All Genders
Healthy Volunteers
NCT04878549

Transcriptomic Responses for the Identification of Pathogens

Led by University of Sheffield · Updated on 2025-03-03

2000

Participants Needed

1

Research Sites

160 weeks

Total Duration

On this page

Sponsors

U

University of Sheffield

Lead Sponsor

C

Christian Medical College, Vellore, India

Collaborating Sponsor

AI-Summary

What this Trial Is About

Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions. Assessment of the host gene expression response to infection in endemic populations has demonstrated significant promise as a new approach to identifying patients with enteric fever and for potential in differentiating between other causes of AUFI. Signatures identified through new data analytic techniques could be developed into a point-of-care test for use in endemic settings. In this multisite diagnostic evaluation study we will collect prospective clinical, laboratory and diagnostic data from two endemic settings to evaluate host gene expression signatures for detecting enteric fever and for determining the cause of AUFI in LMIC settings.

CONDITIONS

Official Title

Transcriptomic Responses for the Identification of Pathogens

Who Can Participate

Age: 2Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 15 to 65 years for adults, or 2 to less than 15 years for pediatric exploratory aims
  • Willingness and ability to provide informed consent (and assent for children aged 8-14 years)
  • Febrile illness without localizing features with fever defined as documented temperature  38�B0C (tympanic/rectal) or  37.8�B0C (axillary/oral) or reported fever in last 24 hours
  • Reported duration of fever between 3 and 14 days, or recently confirmed blood culture indicating enteric fever within 5 days
  • Recent exposure to antimicrobials allowed
  • Controls must be afebrile with temperature  38�B0C (tympanic/rectal) or  37.8�B0C (axillary/oral)
  • Controls must live outside the normal/local catchment area for each hospital site
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent with no willing next of kin or guardian
  • History or suspicion of rheumatological or connective tissue disorders
  • Autoimmune conditions
  • Malignancy
  • Active treatment with immunomodulating medications or for tuberculosis or chronic infections
  • Pregnancy (breastfeeding mothers allowed)
  • Hospitalization for more than 48 hours in the last 4 weeks (for febrile adults) or hospitalization within 4 weeks of recruitment (for controls)
  • Vaccination within 4 weeks prior to admission or recruitment
  • Localizing signs or symptoms sufficient to diagnose cause of acute febrile illness
  • For controls: antimicrobial use within 4 weeks of recruitment
  • Participant reports feeling more unwell than usual on day of enrolment (controls)
  • For pediatric participants: unwillingness of parent/guardian or patient aged 8 to 14 years to provide consent/assent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Christian Medical Centre

Vellore, India

Actively Recruiting

Loading map...

Research Team

F

Farah Shahi

CONTACT

T

Thomas Darton

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here